Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of pharmacological and toxicological methods

• Publication date

  2005-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.VASCN.2005.04.002PMID 15936217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identifying Modulators of hERG Channel Activity Using the PatchXpress® Planar Patch Clamp

  2005cited by this paper
• A Place for High-Throughput Electrophysiology in Cardiac Safety: Screening hERG Cell Lines and Novel Compounds with the Ion Works HTTM System

  2005cited by this paper
• Patch clamping by numbers.

  2004cited by this paper
• Automated high-throughput patch-clamp techniques.

  2004cited by this paper
• Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization.

  2004cited by this paper
• Drug-induced prolongation of the QT interval.

  2004cited by this paper
• Automated Tight Seal Electrophysiology for Assessing the Potential hERG Liability of Pharmaceutical Compounds

  2004cited by this paper
• Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.

  2004cited by this paper
• Trends in ion channel drug discovery: advances in screening technologies.

  2003cited by this paper
• Functional and pharmacological properties of canine ERG potassium channels.

  2003cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper
• Modulation of human ether‐à‐go‐go‐related K+ (HERG) channel inactivation by Cs+ and K+

  2003cited by this paper
• The long QT syndromes: genetic basis and clinical implications.

  2000cited by this paper
• Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.

  1998cited by this paper
• Fundamentals of Anatomy and Physiology

  1997cited by this paper
• HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.

  1996cited by this paper
• Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.

  1995cited by this paper
• A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.

  1995cited by this paper
• Calculation of hydrophobic constant (log P) from pi and f constants.

  1975cited by this paper

• Enlarged Data Sets and Innovative Applicability Domain Characterization Empower ML Models to Reliably Bridge hERG Binding Data Gaps in Diverse Chemicals.

  2025cites this paper
• MultiCBlo: Enhancing predictions of compound-induced inhibition of cardiac ion channels with advanced multimodal learning.

  2024cites this paper
• Experimentally validated modeling of dynamic drug-hERG channel interactions reproducing the binding mechanisms and its importance in action potential duration

  2024cites this paper
• Benchmarking of Small Molecule Feature Representations for hERG, Nav1.5, and Cav1.2 Cardiotoxicity Prediction

  2023cites this paper
• New Aspects of Bilayer Lipid Membranes for the Analysis of Ion Channel Functions

  2022cites this paper
• Zebrafish models for toxicological screening

  2022cites this paper
• Cardiac hERG K+ Channel as Safety and Pharmacological Target.

  2021cites this paper
• Nanotechnology: new opportunities for the development of patch‐clamps

  2021cites this paper
• Case studies in drug discovery

  2021cites this paper
• Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.

  2020cites this paper
• Application of electrophysiological technique in toxicological study: From manual to automated patch-clamp recording

  2020cites this paper
• A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one

  2018cites this paper
• Synthetic Analogues of the Snail Toxin 6-Bromo-2-mercaptotryptamine Dimer (BrMT) Reveal That Lipid Bilayer Perturbation Does Not Underlie Its Modulation of Voltage-Gated Potassium Channels.

  2018cites this paper
• Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism.

  2018cites this paper
• Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti‐Infective Agents: A Systematic Literature Review From the ARITMO Project

  2017cites this paper
• Catch and Patch: A Pipette-Based Approach for Automating Patch Clamp That Enables Cell Selection and Fast Compound Application

  2016cites this paper
• The effect of increasing amitriptyline doses on cardiomyocytes’ electrophysiology – simulation study

  2016cites this paper
• Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential-a safety approach

  2016cites this paper
• Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels

  2016cites this paper
• Sudden cardiac and sudden unexpected death related to antipsychotics: A meta‐analysis of observational studies

  2016cites this paper
• Micro- and nano-technologies for lipid bilayer-based ion-channel functional assays.

  2015cites this paper
• Global Analysis Reveals Families of Chemical Motifs Enriched for hERG Inhibitors

  2015cites this paper
• Enhanced QSAR models for drug‐triggered inhibition of the main cardiac ion currents

  2015cites this paper
• In Vitro Methods for Cardiotoxicity Testing

  2014cites this paper
• Assessing hERG Pore Models As Templates for Drug Docking Using Published Experimental Constraints: The Inactivated State in the Context of Drug Block

  2014cites this paper
• In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats

  2014cites this paper
• Early identification of hERG liability in drug discovery programs by automated patch clamp

  2014cites this paper
• Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.

  2013cites this paper
• High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.

  2013cites this paper
• In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis.

  2013cites this paper
• Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.

  2013cites this paper
• Predicted drug-induced bradycardia related cardio toxicity using a zebrafish in vivo model is highly correlated with results from in vitro tests.

  2013cites this paper
• One-step polymer surface modification for minimizing drug, protein, and DNA adsorption in microanalytical systems.

  2013cites this paper
• Predicting Drug‐Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures

  2013cites this paper
• Lipid bilayer array for simultaneous recording of ion channel activities

  2012cites this paper
• Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.

  2012cites this paper
• Application of Complementary and Alternative Medicine on Neurodegenerative Disorders: Current Status and Future Prospects

  2012cites this paper
• From Omics to Drug Metabolism and High Content Screen of Natural Product in Zebrafish: A New Model for Discovery of Neuroactive Compound

  2012cites this paper
• Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models

  2012cites this paper
• Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.

  2012cites this paper
• Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models

  2012cites this paper
• An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment.

  2012cites this paper
• hERG ion channel pharmacology: cell membrane liposomes in porous-supported lipid bilayers compared with whole-cell patch-clamping

  2012cites this paper
• Development and Validation of an Automated High-Throughput System for Zebrafish In Vivo Screenings

  2012cites this paper
• Voltage‐Gated Sodium Channels as Therapeutic Targets

  2012cites this paper
• Activity at Cardiovascular Ion Channels: A Key Issue for Drug Discovery

  2012cites this paper
• In vitro Testing of Proarrhythmic Toxicity

  2012cites this paper
• Introduction of a Modular Automated Voltage-Clamp Platform and Its Correlation with Manual Human Ether-à-go-go Related Gene Voltage-Clamp Data

  2011cites this paper
• Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.

  2011cites this paper
• Development and Comparison of hERG Blocker Classifiers: Assessment on Different Datasets Yields Markedly Different Results

  2011cites this paper
• Manual whole-cell patch-clamping of the HERG cardiac K+ channel.

  2011cites this paper
• hERG subunit composition determines differential drug sensitivity

  2011cites this paper
• Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations.

  2011cites this paper
• Preclinical Drug Safety and Cardiac Ion Channel Screening

  2011cites this paper
• Pharmacological studies of Cav3.1 T-type calcium channels using automated patch-clamp techniques.

  2011cites this paper
• Impact of new technologies for cellular screening along the drug value chain.

  2010cites this paper
• Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology

  2010cites this paper
• Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals

  2010cites this paper
• Cardiac Ion Channel Safety Profiling on the IonWorks Quattro Automated Patch Clamp System

  2010cites this paper
• Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp.

  2010cites this paper
• The development of high quality seals for silicon patch-clamp chips.

  2010cites this paper
• Screening technologies for ion channel drug discovery.

  2010cites this paper
• Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants.

  2010cites this paper
• Iatrogenic QT Prolongation

  2010cites this paper
• Current Practices in Safety Pharmacology

  2010cites this paper
• 創薬早期における薬剤誘発性 QT 延長リスクの in vivo 評価法に関する研究

  2010cites this paper
• Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform.

  2009cites this paper
• Should Cardiosafety be Ruled by hERG Inhibition? Early Testing Scenarios and Integrated Risk Assessment

  2009cites this paper
• hERG in vitro interchange factors—development and verification

  2009influential citation
• Automated patch clamping using the QPatch.

  2009cites this paper
• Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties

  2009cites this paper
• Quantitative Structure–Activity Relationship Models for Predicting Biological Properties, Developed by Combining Structure‐ and Ligand‐Based Approaches: An Application to the Human Ether‐a‐go‐go‐Related Gene Potassium Channel Inhibition

  2009cites this paper
• Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?

  2009cites this paper
• Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.

  2009cites this paper
• Interaction of hERG Channels and Syntaxin 1A

  2009cites this paper
• Development and optimization of a high-throughput electrophysiology assay for neuronal alpha4beta2 nicotinic receptors.

  2009cites this paper
• Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress.

  2009cites this paper
• Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?

  2008cites this paper
• The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview.

  2008cites this paper
• Evaluation of zebrafish embryos as a model for assessing inhibition of hERG.

  2008cites this paper
• Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.

  2008cites this paper
• Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspective

  2008cites this paper
• The hERG potassium channel and hERG screening for drug-induced torsades de pointes.

  2008cites this paper
• An Ion Channel Library for Drug Discovery and Safety Screening on Automated Platforms

  2008cites this paper
• Integrative Nanobioengineering: Novel Bioelectronic Tools for Real Time Pharmaceutical High Content Screening in Living Cells and Tissues

  2008cites this paper
• A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry.

  2008cites this paper
• Support vector machines classification of hERG liabilities based on atom types.

  2008cites this paper
• Kv1.5 Potassium Channel Inhibitors for the Treatment and Prevention of Atrial Fibrillation

  2008cites this paper
• Biochips: Technologies and applications

  2008cites this paper
• Improved Throughput of PatchXpress hERG Assay Using Intracellular Potassium Fluoride

  2008cites this paper
• High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology

  2008cites this paper
• Potent, selective MCH-1 receptor antagonists.

  2008cites this paper
• Preclinical Cardiac Safety Assessment of Drugs

  2007cites this paper
• Automated voltage-clamp technique.

  2007cites this paper
• Population patch clamp electrophysiology: a breakthrough technology for ion channel screening.

  2007cites this paper
• Application of PatchXpress Planar Patch Clamp Technology to the Screening of New Drug Candidates for Cardiac KCNQ1/KCNE1 (I Ks) Activity

  2007cites this paper
• Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

  2006cites this paper
• ALTERING EXTRACELLULAR POTASSIUM CONCENTRATION DOES NOT MODULATE DRUG BLOCK OF HUMAN ETHER‐A‐GO‐GO‐RELATED GENE (hERG) CHANNELS

  2006cites this paper
• Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety

  2006cites this paper
• Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.

  2006cites this paper